Boilerplate clauses

Boilerplate clauses

This subtopic focuses on boilerplate clauses in commercial business-to-business agreements. For information on commercial clauses more generally, see: Commercial clauses—overview.

For information on boilerplate in business-to-consumer contracts, see the section on ‘Consumer boilerplate’ below.

For information on boilerplate in public sector contracts, see the section on ‘Public sector boilerplate’ below.

The role of boilerplate

Lawyers work on a huge variety of transactions, but all of them will in some way involve written agreements. All of those agreements should contain some boilerplate clauses.

‘Boilerplate’ is the term used to describe the clauses that are included in an agreement to deal with the mechanics of how it works and those legal points that are relevant to most transactions. For further consideration of the role and importance of boilerplate clauses, see Practice Note: The role of boilerplate.

Boilerplate clauses are generally found at the beginning and the end of an agreement. Such clauses are often thought of as standard, miscellaneous provisions, but this is a very dangerous view to adopt. It is not unusual for a boilerplate clause to be the cause of litigation. Since a boilerplate clause

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

TAKE A FREE TRIAL

Latest Life Sciences News

MedTech Europe calls for EU rule changes on electronic instructions for near-patient tests

MedTech Europe has published a booklet calling on EU policymakers to modernise rules to permit electronic instructions for use (eIFUs) for near-patient testing devices. Under current EU In Vitro Diagnostic Medical Devices Regulation 2017/746/EU, paper instructions remain mandatory for near-patient testing devices, while the European Commission recently permitted eIFUs for other medical devices under the Medical Devices Regulation 2017/745/EU through Commission Implementing Regulation (EU) 2025/1234. The trade association argues that nearly 90% of healthcare professionals prefer electronic over paper instructions, citing benefits including improved accessibility, reduced environmental impact, and up-to-date information availability. The booklet highlights that Europe represents approximately 30% of global point-of-care testing by volume, with Germany alone having over 10,000 point-of-care testing analysers installed in healthcare facilities by end-2023. MedTech Europe proposes that paper copies should remain available free of charge upon request, but argues automatic provision is unnecessary when electronic versions are preferred by healthcare professionals.

ABPI announces further extension to VPAG 2026 decision deadline

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to extend the deadline for companies to give notice of leaving the 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) to 14 November 2025, offering a further two-week extension from the previous 31 October deadline. This extension reduces the minimum notice period from two months to six weeks, affording companies extra time to decide amid global uncertainty in the life sciences sector. Companies that fail to give notice by the deadline must remain in the VPAG scheme for 2026, while those opting to leave will transition to the Statutory Scheme for branded medicines.

EMA launches draft reflection paper and consultation on non-human primate use and 3Rs implementation

The European Medicines Agency (EMA) has published a draft reflection paper on non-human primates (NHPs) in safety testing of human medicinal products and opportunities for 3Rs (replacement, reduction and refinement) implementation. The paper outlines scientific and regulatory considerations for NHP use in non-clinical safety testing and highlights opportunities to apply the 3Rs principles within existing guidelines to limit NHP use to a last resort where scientifically justified. EMA has also launched a consultation on the reflection paper, which closes on 31 January 2026.

HEMA publishes draft report on what factors should be considered for HTA

The Health Economics Methods Advisory (HEMA), which guides best practices in international health technology assessment (HTA), has published its first draft report for public comment until 30 October 2025. The report examines whether factors other than health benefits and costs to the system should be considered when deciding if treatments should be recommended. These factors include the burden on families and carers, if treatments address health inequalities, how much risk patients are willing to accept on novel treatments and the value of a diagnosis. It now is inviting comments and views on the findings of the draft report from patients, clinicians, and other stakeholders and is expected to deliver a final report in January 2026. It aims to provide concrete guidance that health technology appraisal organisations worldwide can use to improve their evaluations. HEMA is a partnership among very different healthcare systems from the US, Canada and UK via the Institute for Clinical and Economic Review (ICER) in the US, Canada's Drug Agency (CDA-AMC) and the UK's National Institute for Health and Care Excellence (NICE).